Pacific Biosciences of California Inc (PACB)
1.47
-0.09
(-5.77%)
USD |
NASDAQ |
Apr 23, 16:00
1.49
+0.02
(+1.36%)
After-Hours: 07:40
Pacific Biosciences of California Enterprise Value: 655.21M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 655.21M |
| April 22, 2024 | 679.32M |
| April 19, 2024 | 676.64M |
| April 18, 2024 | 652.53M |
| April 17, 2024 | 636.45M |
| April 16, 2024 | 636.45M |
| April 15, 2024 | 1.021B |
| April 12, 2024 | 1.111B |
| April 11, 2024 | 1.167B |
| April 10, 2024 | 1.154B |
| April 09, 2024 | 1.229B |
| April 08, 2024 | 1.186B |
| April 05, 2024 | 1.159B |
| April 04, 2024 | 1.154B |
| April 03, 2024 | 1.162B |
| April 02, 2024 | 1.175B |
| April 01, 2024 | 1.239B |
| March 28, 2024 | 1.266B |
| March 27, 2024 | 1.258B |
| March 26, 2024 | 1.205B |
| March 25, 2024 | 1.229B |
| March 22, 2024 | 1.247B |
| March 21, 2024 | 1.290B |
| March 20, 2024 | 1.285B |
| March 19, 2024 | 1.237B |
| Date | Value |
|---|---|
| March 18, 2024 | 1.245B |
| March 15, 2024 | 1.277B |
| March 14, 2024 | 1.309B |
| March 13, 2024 | 1.397B |
| March 12, 2024 | 1.336B |
| March 11, 2024 | 1.440B |
| March 08, 2024 | 1.448B |
| March 07, 2024 | 1.491B |
| March 06, 2024 | 1.380B |
| March 05, 2024 | 1.427B |
| March 04, 2024 | 1.569B |
| March 01, 2024 | 1.652B |
| February 29, 2024 | 1.743B |
| February 28, 2024 | 1.754B |
| February 27, 2024 | 1.767B |
| February 26, 2024 | 1.663B |
| February 23, 2024 | 1.631B |
| February 22, 2024 | 1.636B |
| February 21, 2024 | 1.623B |
| February 20, 2024 | 1.679B |
| February 16, 2024 | 1.799B |
| February 15, 2024 | 2.049B |
| February 14, 2024 | 2.003B |
| February 13, 2024 | 1.890B |
| February 12, 2024 | 2.059B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
265.38M
Minimum
Apr 03 2020
9.558B
Maximum
Feb 11 2021
2.480B
Average
2.082B
Median
Oct 08 2020
Enterprise Value Benchmarks
| Cerus Corp | 319.29M |
| Axogen Inc | 316.73M |
| AVITA Medical Inc | 181.60M |
| BioSig Technologies Inc | 16.41M |
| Intellia Therapeutics Inc | 1.157B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -82.02M |
| Revenue (Quarterly) | 58.36M |
| Total Expenses (Quarterly) | 144.74M |
| EPS Diluted (Quarterly) | -0.31 |
| Gross Profit Margin (Quarterly) | 16.40% |
| Profit Margin (Quarterly) | -140.5% |
| Earnings Yield | -82.31% |
| Normalized Earnings Yield | -75.48 |